Generation Bio (NASDAQ:GBIO – Get Rating) and Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Profitability
This table compares Generation Bio and Citius Pharmaceuticals' net margins, return on equity and return on assets.
Get
Generation Bio alerts:
| Net Margins | Return on Equity | Return on Assets |
| Generation Bio | N/A | -39.52% | -31.03% |
| Citius Pharmaceuticals | N/A | -24.78% | -22.97% |
Institutional and Insider Ownership
93.9% of Generation Bio shares are held by institutional investors. Comparatively, 25.4% of Citius Pharmaceuticals shares are held by institutional investors. 20.7% of Generation Bio shares are held by insiders. Comparatively, 14.8% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Generation Bio has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Generation Bio and Citius Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Generation Bio | 0 | 2 | 5 | 0 | 2.71 |
| Citius Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Generation Bio presently has a consensus price target of $16.75, suggesting a potential upside of 165.03%. Citius Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 367.29%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Generation Bio.
Valuation & Earnings
This table compares Generation Bio and Citius Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Generation Bio | N/A | N/A | -$119.15 million | ($2.34) | -2.70 |
| Citius Pharmaceuticals | N/A | N/A | -$23.05 million | ($0.20) | -5.35 |
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Citius Pharmaceuticals beats Generation Bio on 6 of the 11 factors compared between the two stocks.
About Generation Bio
(Get Rating)
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Citius Pharmaceuticals
(Get Rating)
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
